BIO Stock Recent News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced its participation in BIO-Europe Spring®, which is being held in Milan, Italy, March 17-19, 2025. During the Spring partnering event, members of Enveric's management team are conducting one-on-one meeting.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of bluebird bio, Inc. (NasdaqGS: BLUE) to Carlyle Group and SK Capital Partners, LP. Under the terms of the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right if blue.

BIO-key (BKYI) Partners with California Ed Tech JPA to Make Identity & Access Management Solutions Available to 195 Member Institutions and 2.6M Students.

CHATHAM, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D.

Review Bio-Rad's (BIO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of bluebird bio, Inc. (NasdaqGS: BLUE) to Carlyle Group and SK Capital Partners, LP. Under the terms of the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right if bluebird's curr.

Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio.

Bio-Rad witnesses growth across the Clinical Diagnostics segment in the fourth quarter, primarily driven by an increased demand for quality control and blood typing products.

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Jon DiVincenzo - President & Chief Operating Officer Roop Lakkaraju - Executive Vice President & Chief Financial Officer Norman Schwartz - Chairman of the Board, President & Chief Executive Officer Conference Call Participants Dan Leonard - UBS Brandon Couillard - Wells Fargo Jack Meehan - Nephron Research Conor McNamara - RBC Capital Markets Tycho Peterson - Jefferies Operator Thank you for standing by. My name is Prila [ph] and I will be your conference operator today.

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.90 per share, missing the Zacks Consensus Estimate of $2.93 per share. This compares to earnings of $3.10 per share a year ago.